Abingworth

Adiana, Inc. engages in the development and testing of transcervical sterilization system for permanent birth control. It develops Complete TCS, which consists of a radiofrequency generator, delivery catheter, and implantable matrix. The company was founded in 1997 and is based in Redwood City, California. As of March 16, 2007, Adiana, Inc. is a subsidiary of CYTYC Corp.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

IMI Intelligent Medical Implants develops and markets intelligent retinal implant systems for degenerative retinal disorders. The company offers The Intelligent Retinal Implant System, an adaptive visual prosthesis that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration. IMI Intelligent Medical Implants was founded in 2002 and is based in Zug, Switzerland.

Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses. Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

Sientra, Inc., a medical device company, develops and markets products focusing on the plastic surgery and aesthetics market. The company is based in Santa Barbara, California. Sientra is committed to providing plastic surgeons with intuitive, elegant solutions—as reflected in its innovative round and shaped product lines. It offers breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders.

Magellan Diagnostics, Inc., a medical device company, develops and manufactures point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. Its products include LeadCare II, a blood lead testing system; LeadCare Ultra, which provides blood lead results for laboratories; and LeadCare Plus, a solution for laboratories with smaller volumes for performing lead testing in house. The company also provides various analytical services, such as lead and heavy metal exposure, monitoring exposure in employees, and testing. It offers solutions for clinicians, public health providers, managed care organizations, and families and communities. Magellan Diagnostics, Inc. was formerly known as Magellan Biosciences, Inc. The company was founded in 2004 and is headquartered in North Billerica, Massachusetts. Magellan Diagnostics, Inc. operates as a subsidiary of Magellan Biosciences, Inc.

Sonitus Medical Inc., is a privately held medical device company committed to providing innovative and clinically effective hearing solutions that Otologists, ENTs, and Audiologists can use to help their patients rejoin the conversation of life. As an emerging leader in bone conduction hearing devices, Sonitus Medical currently markets the SoundBite Hearing System, the world's first non-invasive and removable hearing solution that imperceptibly transmits sound via teeth. Relying on the principle of bone conduction, this nearly invisible ITM (in-the-mouth) hearing system is a simple and non-surgical solution that is currently FDA cleared as a prosthetic device for the treatment of single sided deafness and conductive hearing loss. Intended future applications for this platform technology include indications for hearing disorders such as mixed hearing loss and tinnitus, as well as consumer and covert communications. Founded in June 2006, Sonitus Medical is headquartered in San Mateo, California.

Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics, Inc. has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Gynesonics, Inc. designs and develops minimally invasive solutions for symptomatic uterine fibroids in women. The company offers Sonography-Guided Transcervical Fibroid Ablation (Sonata) System(The Sonata System) for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance serving customers in the European Union. Gynesonics, Inc. was founded in 2005 and is based in Redwood City, California with an additional location in Beuningen, the Netherlands.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

IFM Tre, Inc. is a biopharmaceutical company developing a suite of small-molecule antagonists. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurodegenerative diseases. IFM Tre was founded in 2018 and is based in the United States. As of May 7, 2019, IFM Tre, Inc. operates as a subsidiary of Novartis AG.

Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success. For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutions include mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise.

Gynesonics, Inc. designs and develops minimally invasive solutions for symptomatic uterine fibroids in women. The company offers Sonography-Guided Transcervical Fibroid Ablation (Sonata) System(The Sonata System) for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance serving customers in the European Union. Gynesonics, Inc. was founded in 2005 and is based in Redwood City, California with an additional location in Beuningen, the Netherlands.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways.

Ascend supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

Jasper Therapeutics, Inc., a biotechnology company, develops therapeutic agents for hematopoietic stem cell transplants and gene therapies. It offers JSP191, a humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, which binds to human CD117, a receptor for stem cell factor that is expressed on the surface of hematopoietic stem and progenitor cells. Jasper Therapeutics, Inc. was incorporated in 2018 and is based in Menlo Park, California.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.

Glycomine, Inc. develops nanomedicines for rare genetic disorders. It focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. The company was incorporated in 2014 and is based in San Carlos, California.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Lorantis develops products for the selective treatment of immunological and inflammatory diseases. It develops therapeutics for immunological diseases, including allergy, asthma, autoimmune diseases, and transplant regulation. The company is based in Cambridge, United Kingdom.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Trucode Gene Repair, Inc. operates a triplex gene editing platform for curing genetic diseases. It focuses on sickle cell disease and cystic fibrosis. The company develops a pipeline of novel, proprietary therapeutic products for high-penetrance disease genes to alleviate and cure genetic disorders in patients. The company was founded in 2016 and is based in South San Francisco, California.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Realm Therapeutics is a biopharmaceutical company passionately committed to leveraging its proprietary technologies to protect and improve the health of adults and children. The Company's drug development focus, utilizing its immunomodulatory formulations, is targeted initially on developing small molecule therapies in inflammatory diseases with potential application in dermatology and ophthalmology, and the potential for broad applicability across a number of other diseases.

Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer-reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both invariant detection and interpretation. The company was founded in 2011 and is based in Menlo Park, California.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success. For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutions include mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Kspine was developing implantable medical devices for the treatment of spine disorders.

Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy at low vol­umes and reduced con­sum­ables costs. In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners. Labcyte was founded in 2000 and is based in San Jose, California, United States.

IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis

GelTex Pharmaceuticals develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. It also develops small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Its focus areas include hyperphosphatemia, hypercholesterolemia, cancer, iron overload, and infectious diseases. GelTex Pharmaceutics is based in Waltham Massachusetts.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Jasper Therapeutics, Inc., a biotechnology company, develops therapeutic agents for hematopoietic stem cell transplants and gene therapies. It offers JSP191, a humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, which binds to human CD117, a receptor for stem cell factor that is expressed on the surface of hematopoietic stem and progenitor cells. Jasper Therapeutics, Inc. was incorporated in 2018 and is based in Menlo Park, California.

Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma The NF-κB Pathway and Novel Oncology Target (GADD45β/MKK7), Research and Development pipeline and related indications. The company was incorporated in 2012 and is based in Cambridge, United Kingdom.

Fisher BioImage ApS, a life science company, develops and sells assays for monitoring protein translocations and protein interactions in living cells. It provides Redistribution technology, which helps to monitor cell-based protein translocation assays using fluorescent protein reporters. The company offers assays to pharmaceutical and biotechnology companies, as well as to academic groups for basic research.

Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

Nido Surgical, Inc. develops medical instrument for heart surgery. The company was founded in 2014 and is based in Needham, Massachusetts.

Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Xenogen Biosciences Corporation offers animal production and phenotyping services to biopharmaceutical companies and biomedical researchers. The company also offers DNA microinjection, transgene integration analysis, specialty strain package, various strains of mice, DNA microinjection, and transgene integration analysis packages, as well as transgenic production, phenotyping, and custom gene targeting programs. Its services are used to create bioluminescent animal models to test the effects of a drug on a gene/protein in a biological system. Xenogen Biosciences Corporation was formerly known as Chrysalis DNX Transgenic Sciences. The company is based in Cranbury, New Jersey. As of December 11, 2009, Xenogen Biosciences Corporation operates as a subsidiary of Taconic Farms, Inc.

They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

Chroma Therapeutics Ltd. develops novel small molecule drugs based on chromatin biology and novel cell accumulation approaches for targeted cancer and inflammation treatments. Its products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for the treatment of cancer; and CHR-2845, a targeted solution for haemotological malignancies. The company was founded in 2000 and is based in Abingdon, United Kingdom.

VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

VirionHealth Limited, a biotechnology company, develops novel therapeutics and biological therapeutics for respiratory viral infections and antiviral. The company also focuses on prevention and treatment of influenza and respiratory syncytial viruses. VirionHealth Limited was founded in 2015 and is based in Coventry, United Kingdom.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Adaptate is a biotherapeutics company that develops antibodies to modulate gamma delta T cells in situ. The company was founded in 2019 by Adrian Hayday and is headquartered in London.

Quantum Dot is a bioscience company that is focused on the development and commercialization of biomolecular detection solutions. The company offers Qdot nanocrystals for clinical applications. Quantum Dot was founded by Joel Martin in 1998. It is based in Hayward, California.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer.

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.

Pathwork Diagnostics is based in Redwood City, California. The company develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.

Pathwork Diagnostics is based in Redwood City, California. The company develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.

Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway. Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients.

Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses. Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

Nido Biosciences currently operates in healthcare services. Nido Biosciences specializes in the fields of biotechnology, healthcare, and personal health. It is currently in stealth mode and was founded in 2018.

inMediata, formerly known as Secure EDI is a technology company dedicated to increasing the efficiency and reducing the cost of healthcare. It creates seamless connections among providers and payers for sharing information and providing secure, on-line processing of claim and payment transactions. The company provides electronic solutions for efficiency in dental and health care offices through seamless interfaces between payers and providers. Its solutions include real-time adjudication of claims, electronic funds transfer, converting paper to electronic along with a full range of electronic transactions.

Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Virion’s mission is a developer of biological antivirals creates to offer improved therapeutics for respiratory viral infections. The company's antivirals focus on prevention and treatment of influenza and respiratory syncytial virus (RSV), enabling doctors to get a broad-spectrum therapy for respiratory viral infections, potentially simplifying and accelerating treatment by removing the need for differential diagnosis.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

SFJ Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the clinical development and registration of pharmaceutical products in Japan. The company was incorporated in 2008 and is based in Pleasanton, California.

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered. They have assembled a team of leading scientists and ex-Big Pharma advisors with many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.